REVELATION BIOSCIENCES, INC.
REVB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for REVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · REVB
Revelation Biosciences is a clinical-stage life science company focused on developing product candidates for inflammatory and fibrotic diseases, currently facing a going concern uncertainty due to limited cash runway.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for REVELATION BIOSCIENCES, INC..
Revelation Biosciences is a clinical-stage life science company focused on developing product candidates for inflammatory and fibrotic diseases, currently facing a going concern uncertainty due to limited cash runway.
- Revelation Biosciences is a clinical-stage life science company [sec_mda · as of 2026-02-26].
- As of June 30, 2026, the company had cash and cash equivalents of $11.5 million and an accumulated deficit of $55.8 million [sec_mda · as of 2026-08-06].
- The company has funded operations through the issuance and sale of common stock, preferred stock, and warrants, raising net proceeds of $75.9 million since inception [sec_mda · as of 2026-08-06].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, as current cash is not expected to sustain operations for one year after the June 30, 2026 financial statements [sec_mda · as of 2026-08-06].
- The company has never generated revenue and expects to continue incurring significant operating losses and negative cash flows [sec_mda · as of 2026-05-07].
What works
- The company has raised $75.9 million in net proceeds from equity and warrant sales since inception, indicating some investor support [sec_mda · as of 2026-08-06].
- The company is a clinical-stage entity with a focus on inflammatory and fibrotic diseases, which are areas of high unmet medical need [sec_mda · as of 2026-02-26].
What to weigh
- As of June 30, 2026, the company had only $11.5 million in cash and cash equivalents, with an accumulated deficit of $55.8 million [sec_mda · as of 2026-08-06].
- Management has stated that current cash is insufficient to sustain operations for one year after the June 30, 2026 financial statements, raising substantial doubt about the company as a going concern [sec_mda · as of 2026-08-06].
- The company has never generated revenue and expects to continue incurring significant operating losses and negative cash flows for the foreseeable future [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
The company has a going concern issue due to insufficient cash.
“We anticipate that our current cash and cash equivalents balance will not be sufficient to sustain operations within one-year after the date that our unaudited condensed consolidated financial statements for June 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 6, 2026
The company has raised $75.9 million in net proceeds from equity and warrant sales.
“Since our inception to June 30, 2026, we have funded our operations from the issuance and sale of our common stock, preferred stock and warrants, from which we have raised net proceeds of $75.9 million.”
SEC MD&A · August 6, 2026
The company has an accumulated deficit of $55.8 million as of June 30, 2026.
“As of June 30, 2026, we had available cash and cash equivalents of $11.5 million and an accumulated deficit of $55.8 million.”
SEC MD&A · August 6, 2026
The company has never generated revenue.
“We have never generated revenue and do not expect to generate revenue from product sales unless and until we successfully complete development and obta”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Current cash of $11.5M as of June 30, 2026 is insufficient to sustain operations for one year, raising substantial doubt about the company's ability to continue [sec_mda · as of 2026-08-06].
- No revenue generation — The company has never generated revenue and does not expect to until successful development and regulatory approval [sec_mda · as of 2026-05-07].
- Significant accumulated deficit — Accumulated deficit of $55.8 million as of June 30, 2026, with ongoing operating losses [sec_mda · as of 2026-08-06].
- Dependence on future financing — The company plans to seek additional funding through public or private equity or debt financings, which may not be available [sec_mda · as of 2026-08-06].
What to watch
- Ability to secure additional funding to address the going concern issue [sec_mda · as of 2026-08-06].
- Progress in clinical development of product candidates for inflammatory and fibrotic diseases [sec_mda · as of 2026-02-26].
- Any updates on regulatory interactions or data from ongoing studies [sec · filed 2026-01-29].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run REVELATION BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REVELATION BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
13.5 months
D/E 0.24 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$589K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 323,241 | $388K |
| sabby management, llc | 99,432 | $119K |
| geode capital management, llc | 43,195 | $52K |
| vanguard fiduciary trust co | 13,127 | $16K |
| xtx topco ltd | 11,385 | $14K |
| royal bank of canada | 747 | $1K |
| bnp paribas asset management holding s.a. | 9 | $11 |
| caitong international asset management co., ltd | 1 | $1 |
Short Interest
as of Apr 30, 2026- % of float
- 0.6%
- Days to cover
- 0.3
- Shares short
- 22,511
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
REVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for REVELATION BIOSCIENCES, INC.?
Revelation Biosciences is a clinical-stage life science company focused on developing product candidates for inflammatory and fibrotic diseases, currently facing a going concern uncertainty due to limited cash runway.
What is REVELATION BIOSCIENCES, INC.'s lead drug candidate?
REVELATION BIOSCIENCES, INC.'s most advanced tracked candidate is gemini (Phase 2) for Renal Insufficiency, Chronic.
Who is the CEO of REVELATION BIOSCIENCES, INC.?
Mr. James M. Rolke is the chief executive officer of REVELATION BIOSCIENCES, INC. (REVB).
Where is REVELATION BIOSCIENCES, INC. headquartered?
REVELATION BIOSCIENCES, INC. (REVB) is headquartered in San Diego, CA, United States.
What therapeutic areas does REVELATION BIOSCIENCES, INC. focus on?
REVELATION BIOSCIENCES, INC. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.